- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03051503
Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy
February 22, 2017 updated by: Dr.mohamad farouk mohamad, South Egypt Cancer Institute
to determine the safety, efficacy and tolerability of transdermal fentanyl in patients undergoing mastectomy, as well as the postoperative consumption of analgesic.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: mohamad F mohamad, MD
- Phone Number: +201093942354
- Email: mfaroukma@gmail.com
Study Locations
-
-
-
Assuit, Egypt, 171516
- Recruiting
- South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- ASA I - II patients
- aged 30-60 years
- body weight ranged between 65-10kg
Exclusion Criteria:
- Patients with history of allergy to morphine
- chronic intake of analgesics or non-steroidal anti-inflammatory drug 24 h prior to surgery,
- there was a history of a psychiatric disorder patients weight was less then 50kg.
- impaired kidney function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: The Transdermal Therapeutic System-Fentanyl (TTS-F) group
(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
|
(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
Other Names:
|
Placebo Comparator: Intravenous patient-controlled analgesia (PCA) morphine
IV (PCA) morphine for pain in the postoperative period.
|
IV PCA morphine for pain in the postoperative period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total dose of morphine consumption in the first 48 hours postoperative
Time Frame: 48 hours
|
Total dose of I.V. PCA morphine consumption in the first 48 hours postoperative
|
48 hours
|
Visual Analogue Scale
Time Frame: 48 hours
|
Pain measurement scale
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Level of stress hormones
Time Frame: 48 hours
|
Cortisol levels
|
48 hours
|
Side effects related to the opioids
Time Frame: 48 hours
|
Nausea and vomiting; Itching; Respiratory depression.
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ahmed H Othman, MD, Cancer Institute, Anesthesia, Intensive Care, and Pain Management, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2017
Primary Completion (Anticipated)
April 1, 2017
Study Completion (Anticipated)
April 1, 2017
Study Registration Dates
First Submitted
February 3, 2017
First Submitted That Met QC Criteria
February 8, 2017
First Posted (Actual)
February 13, 2017
Study Record Updates
Last Update Posted (Actual)
February 24, 2017
Last Update Submitted That Met QC Criteria
February 22, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
- Morphine
Other Study ID Numbers
- 228
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Eli Lilly and CompanyActive, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial CancerUnited States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Pittsburgh; Case Western Reserve...RecruitingBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Stage III Breast CancerUnited States
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
Clinical Trials on The Transdermal Therapeutic System-Fentanyl (TTS-F)
-
Alza Corporation, DE, USACompleted
-
Janssen-Cilag Ltd.Completed
-
Alza Corporation, DE, USACompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Preceptis Medical, Inc.Completed
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Korea, Ltd., KoreaCompletedChronic PainKorea, Republic of
-
Janssen Research & Development, LLCCompleted